Enabling and Enhancing Subcutaneous Administration of Monoclonal Antibodies Using ENHANZE® Drug Delivery Technology (Recombinant Human Hyaluronidase, rHuPH20).

Technology Forum Presented By: Halozyme

Date/Time: Sunday, July 21, 2019 - 10:30 AM to 11:30 AM
Log in to Add to My Schedule

Description:

Open to all registered attendees on a complimentary basis, these forums offer in-depth coverage of technologies and services hosted by the presenting companies.

Enabling and Enhancing Subcutaneous Administration of Monoclonal Antibodies Using ENHANZE® Drug Delivery Technology (Recombinant Human Hyaluronidase, rHuPH20).
David Kang, Associate Director, Drug Delivery, Halozyme Therapeutics

Monoclonal antibodies (mAbs) have continued to gain popularity as a class of drugs for the treatment of various diseases, including oncologic,  immunologic, neurologic conditions and a variety of rare diseases.  One of the key reasons for the attractiveness of mAbs is high target specificity.  However, a significant challenge  associated with therapeutic mAbs are the generally high doses and volumes, requiring delivery as a slow intravenous (IV) infusion.  In this session, we will discuss an alternative to IV infusions of mAbs using the ENHANZE® drug delivery technology to deliver large volumes of drugs rapidly through the subcutaneous route of administration.